Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MLTA3698A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | ACTIVE_COMPARATOR | - |
| C | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MLTA3698A | DRUG | Subcutaneous repeating dose |
| adalimumab | DRUG | Subcutaneous repeating dose |
| leflunomide | DRUG | Stable dose if not on methotrexate |
| methotrexate | DRUG | Stable dose if not on leflunomide |
| placebo | DRUG | Subcutaneous repeating dose |
Inclusion Criteria: * Diagnosis of RA according to the 1987 revised ACR Criteria for the Classification of RA for at least 6 months prior to screening * Positive for rheumatoid factor or anti-cyclic citrullinated peptide (CCP) antibody, or both * Active disease, defined as: CRP \>= 1.0 mg/dL; swoll...
Top 20 of 28 competitors
MLTA3698A is an investigational small molecule being studied for the treatment of active rheumatoid arthritis. It is designed to be used in combination with a disease-modifying anti-rheumatic drug (DMARD) and was evaluated against adalimumab plus a DMARD in a Phase 2 clinical trial.
MLTA3698A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this small molecule for the treatment of rheumatoid arthritis.
MLTA3698A is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is not currently in active clinical trials.
MLTA3698A has been studied in one completed Phase 2 trial, identified as NCT01225393. This randomized, double-blind, placebo-controlled study enrolled 211 participants with active rheumatoid arthritis and compared MLTA3698A plus a DMARD against adalimumab plus a DMARD.
No, MLTA3698A is not the same as adalimumab. In the Phase 2 clinical trial NCT01225393, MLTA3698A in combination with a DMARD was compared with adalimumab in combination with a DMARD, indicating they are distinct treatments being evaluated against each other.